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miR-199a-5p suppresses human bladder
cancer cell metastasis by targeting CCR7
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Abstract
Background: C-C chemokine receptor type 7 (CCR7) overexpression correlated with lymphatic metastasis and poor
prognosis is a major obstacle to bladder cancer treatment. Recent studies have revealed that miR-199a-5p was
significantly abnormal expressed in several solid tumors and functioned as oncogene or tumor suppressor. This
study was aimed to further investigate the effects of miR-199a-5p on the cell metastasis mediated by CCR7 in
bladder cancer.
Methods: Quantitative Real Time PCR (qRT-PCR) was firstly performed to identified the expression of miR-199a-5p
and CCR7 in human bladder cancer samples and cell lines. Following that, the effects of miR-199a-5p on cell
migratory and invasive activities were assessed by wound healing and Matrigel invasion assays, respectively. Finally,
luciferase reporter assay and western blot were employed to investigate whether CCR7 could directly interact with
miR-199a-5p.
Results: miR-199a-5p downregulation and CCR7 upregulation were firstly observed in bladder cancer samples and
cell lines. In addition, both miR-199a-5p downregulation and CCR7 upregulation were significantly involved in
bladder cancer clinicopathological features. Moreover, overexpression of miR-199a-5p could inhibit baldder cancer
cell migration and invasion. miR-199a-5p was confirmed to be able to target the 3′ untranslated region (UTR) of
CCR7 and regulate the expression of CCR7, Matrix metalloproteinases 9 (MMP-9) and Epithelial-Mesenchymal
Transition (EMT)-related proteins.
Conclusion: Our findings added newer insights into the multifaceted role played by miR-199a-5p/CCR7 in bladder
cancer, prompting for the first time this miRNA/chemokine axis that regulates cell metastasis. The results strongly
supported miR-199a-5p as a potential therapeutic agent and diagnostic marker of bladder cancer.
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Background
Bladder cancer, a major cause of morbidity and mortality
worldwide, is the fourth most common cancer in men.
Approximately 25 % of bladder cancer cases are muscle
invasive which is more aggressive and with a much
worse prognosis [1, 2]. Due to the introduction of
cisplatin-based combination chemotherapy, the survival
among patients with locally advanced bladder cancer has
been improved in the past 30 years. While the recur-
rence and mortality is still high to those with muscle-
invasive bladder cancer. Besides, patients with recurrent
or metastatic bladder cancer just remains 14–15 months
with cisplatin-based chemotherapy [3–5]. Thus, inhib-
ition of the metastasis is considered to be a promising
strategy for bladder cancer therapy.
CCR7, a member of the G-protein-coupled hepta-helical
receptors (GPCR) family, is substantially expressed on
naive T cells, B cells, and mature dendritic cells [6–8]. Pre-
vious studies have demonstrated CCR7 overexpression
correlates with lymphatic metastasis and poor prognosis
in breast cancer, colon cancer, prostate cancer and gastric
cancer [9–12]. In our previous study, we also have found
that CCR7 and its ligand CCL21 promote T24 cell prolif-
eration and enhance its migration and invasion via upreg-
ulation MMP-2 and MMP-9 [13].
Recently, microRNAs, a class of 19–24 nucleotides
small non-coding RNAs, have been proved to be
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involved in pathogenesis of cancer by either degradation
of mRNA or inhibition of its translation [14, 15]. In
bladder cancer, miRNAs also have been found to play a
crucial role in its development, progression and metasta-
sis, such as miR-27a, miR-143, and miR-150 [16–18].
However, to the best of our knowledge, the relationship
between miR-199a-5p and CCR7 in bladder cancer has
not been reported to date.
In this study, the miR-199a-5p expression was first iden-
tified to be significantly downregulated in human bladder
cancer clinical samples and cell lines by qRT-PCR. We
found that there was a positive correlation between
199a-5p downexpression and lymphatic metastasis.
Overexpression of miR-199a-5p significantly inhibited




Forty fresh bladder cancer tissue samples and paired adja-
cent normal tissue samples were obtained from patients
who had undergone transurethral bladder tumor resection
or radical cystectomy at Department of Urology, Zhejiang
Provincial People’s Hospital after surgical resection. All
collected tissue samples were immediately frozen in liquid
nitrogen and stored at −80 °C until further use. The insti-
tutional ethics committee of Zhejiang Provincial People’s
Hospital approved the study, and written informed con-
sent was also obtained from all patients.
Cell lines and cell culture
The human bladder cancer T24 cell line and human
normal bladder epithelial cell line SV-HUC-1 were
purchased from the Shanghai Institutes for Biological
Sciences, the Chinese Academy of Sciences (Shanghai,
China). The T24 and SV-HUC-1 were maintained at
37 °C, 5 % CO2 in DMEM (Invitrogen, Carls-bad,
CA, USA) or F12K medium (Invitrogen, Carlsbad,
CA, USA) supplemented with 10 % fetal bovine
serum (FBS), respectively.
RNA isolation and quantitative real-time PCR
Total RNA was extracted using Trizol (Invitrogen) and
treated with RNase-free DNase (Qiagen). Power SYBR
qPCR and miRNA qRT-PCR detection kit (Applied Bio-
systems) were performed in a qRT-PCR detection system
(ABI, USA) according to the manufacturer’s protocols.
miR-199a-5p mimics and transfection
miR-199a-5p mimics and the negative control were ob-
tained from Biomics Biotechnology Inc (Nanjing, China).
Transfections were performed using Lipofectamine™
2000 Reagent (Invitrogen, CA, USA) according to the
protocol.
Wound-healing assay
Cell migration activity was evaluated by wound healing
assay. After 48 h transfection, T24 cells were wounded by
scraping of three parallel lines with a 200 ml pipette tip,
and then washed three times with PBS and incubated in
serum-free medium. The wounds were photographed at 0
and 24 h after wounding under a microscope.
Matrigel invasion assay
Matrigel invasion assay was carried out to assay the cells
invasive capacity with a chamber containing a polycarbon-
ate membrane (8 μm pore size) and coated with a layer of
extracellular matrix gel (BD Biosciences) according to the
manufacturer’s instructions. After 72 h transfection, the
number of cells that penetrated the matrigel was counted
from six randomly selected fields per membrane.
Adhesion assay
Microtiter wells were coated with matrix gel (BD Biosci-
ences) at 37 °C, 4 h. Then the wells were blocked for 1 h
with 1 % BSA in PBS. After 48 h transfection, 105 cells/
well were seeded in serum-free medium. After 1 h adhe-
sion, non-adherent cells were washed away with PBS.
The colorimetric MTT-assay was used to determine the
number of adherent cells.
Luciferase reporter assay
The 3′UTR encompassing the target sequence for miR-
199a-5p of CCR7 was synthesized and cloned into
pMiR-Report vector (Ambion) at HindIII and SpeI sites.
After 48 h transfection, luciferase activity was measured
using a Glomax 96 luminometer (Promega) according to
the manufacturer’s protocols.
Western blot
After 48 h transfection, cells were harvested and lysed. Pro-
teins were separated by 10 % SDS-PAGE, transferred to
PVDF membranes (Millipore, USA) and blotted with pri-
mary antibodies (rabbit anti-CCR7, 1:1000, Abcam, USA;
rabbit anti-MMP-9, 1:1000, Abcam, USA; rabbit anti-E-
cadherin, 1:1000, Abcam, USA; rabbit anti-Vimentin,
1:5000, Abcam, USA; rabbit anti-β-actin, 1:1000, Abcam,
USA) at 4 °C overnight followed by incubation with horse-
radish peroxidase labeled secondary antibodies for 2 h at
room temperature.
Statistics
Data are expressed as means ± SD. Clinicopathological
parameters were compared using the χ2 test, and con-
tinuous variables were compared using the Student’s t-
test. P value < 0.05 was considered significant.
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Results
miR-199a-5p expression was downregulated and CCR7
expression was upregulated in human bladder cancer
tissue samples and cell lines
To determine whether miR-199a-5p was involved in the
tumourigenesis of human bladder cancer, we evaluated the
expression levels of miR-199a-5p in human bladder cancer
tissue samples and cell lines by qRT-PCR. As shown in
Fig. 1a and b, the expression of miR-199a-5p was 3.36-fold
and 5.20-fold lower in tumour tissues and bladder cancer
cells compared with that in paired adjacent normal tissue
or normal cell line SV-HUC-1, respectively. Next, we de-
tected CCR7 expression in human bladder cancer tissue
samples and cell lines. Contrary to miR-199a-5p, the ex-
pression of CCR7 was 6.60-fold and 10.53-fold higher in
tumour tissues and bladder cancer cells compared with that
in paired adjacent normal tissue or normal epithelial cell
line SV-HUC-1, respectively (Fig. 1c, d).
Correlation of miR-199a-5p and CCR7 expression with
clinicopathological factors
As shown in Table 1, miR-199a-5p downregulation was
correlated with TNM stage (P < 0.001), Histological
grade (P = 0.003), Tumor invasion depth (T) (P < 0.001)
and Lymph node metastasis (N) (P < 0.001). Consistent
with miR-199a-5p, CCR7 upregulation was also corre-
lated with TNM stage (P < 0.011), Histological grade (P
= 0.001), Tumor invasion depth (T) (P < 0.001) and
Lymph node metastasis (N) (P < 0.001) (Table 2). How-
ever, there was no statistical difference between age,
Fig. 1 The expression of miR-199a-5p and CCR7 in human bladder cancer tissue samples and cell lines. a Relative expression of miR-199a-5p in
bladder cancer tissues compared with corresponding normal tissues. b Relative expression of miR-199a-5p in bladder cancer T24 cells and human
normal bladder epithelial cell (SV-HUC-1). c Relative expression of CCR7 in bladder cancer tissues compared with corresponding normal tissues.
d Relative expression of CCR7 in bladder cancer T24 cells and human normal bladder epithelial cells (SV-HUC-1). Data are expressed as means ±
SD of three independent experiments. **P < 0.01 compared with the normal bladder epithelial cell (SV-HUC-1) or normal tissues
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gender and tumor size and the miR-199a-5p or CCR7
expression level.
Overexpression of miR-199a-5p inhibited the migratory
and invasive activity of bladder cancer cells
In order to examine the effect of miR-199a-5p on the me-
tastasis of baldder cancer cells, we overexpressed miR-
199a-5p in T24 cells. The efficiency of transfection was
confirmed by qRT-PCR (Fig. 2d). Wound-healing assay
showed a significant reduction of cell migration in miR-
199a-5p-transfected cells compared with the negative con-
trol (Fig. 2a). In addition, Matrigel invasion assay showed
that the number of invasive cells in the miR-199a-5p-
transfected group was significantly decreased compared
with that in the negative control group (Fig. 2b). More-
over, after transfected with miR-199a-5p, the adhesion ac-
tivity was also decreased in T24 cells (Fig. 2c).
miR-199a-5p directly targeted the 3′UTR of CCR7 and
inhibited the expression of MMP-9 and EMT-related
proteins in T24 cells
To test whether miR-199a-5p could directly interact
with CCR7 in bladder cancer cells, we found that the
3′UTR of CCR7 contained a potential miR-199a-5p
binding site through bioinformatics software (micro-
RNA.org) (Fig. 3a). As shown in Fig. 3b, after trans-
fected with miR-199a-5p, the relative luciferase
activity in the wild-type group was obviously sup-
pressed compared with the mut-type group. Mean-
while, a dramatic decrease of CCR7 was observed in
miR-199a-5p-transfected cells compared with the
negative control (Fig. 3d). However, after transfected
with miR-199a-5p, there was no difference in mRNA
level of CCR7 expression (Fig. 3c).
Meanwhile, we also examined the effects of miR-199a-
5p/CCR7 on the expression of MMP-9 and EMT-related
vimentin and E-cadherin. As shown in Fig. 3d, miR-199a-
5p overexpression could significant decrease MMP-9 and
vimentin expression, while E-cadherin expression obvi-
ously increased in miR-199a-5p-transfected T24 cells
compared with the negative control.
Discussion
In this study, we provided evidence that miR-199a-5p/
CCR7 plays an essential role in both the suppression of
the EMT process and the metastatic ability of bladder
Table 1 Correlation between miR-199a-5p expression and clinicopathological characteristics of bladder cancer patients
Characteristics Total Expression of miR-199a-5p P value
High (n = 13) Low (n = 27)
Age 0.758
≤ 60 16 6(37.5 %) 10(62.5 %)
> 60 24 7(29.2 %) 17(70.8 %)
Gender 0.316
Male 25 10(40 %) 15(60 %)
Female 15 3(20 %) 12(70 %)
TNM stage <0.001**
0/I 5 3(60 %) 2(40 %)
II/III/IV 35 10(28.6 %) 25(71.4 %)
Tumor size 0.501
< 3 cm 16 4(40 %) 12(60 %)
≥ 3 cm 24 9(37.5 %) 15(62.5 %)
Histological grade 0.003**
PUNLMP/Low-grade 21 11(52.3 %) 10(47.7 %)
High-grade 19 2(10.5 %) 17(89.5 %)
Tumor invasion depth (T) <0.001**
Tis, Ta, T1 19 12(60 %) 7(40 %)
T2, T3 or above 21 1(10 %) 20(90 %)
Lymph node metastasis (N) <0.001**
N0 12 5(41.7 %) 7(58.3 %)
N1 or above 28 8(28.6 %) 20(71.4 %)
PUNLMP papillary urothelial neoplasm of low malignant potential; Low-grade lowgrade papillary urothelial carcinoma; High-grade high-grade papillary urothelial
carcinoma (http://www.pathology.jhu.edu/bladdercancer/disease_info.cfm). TNM according to the seventh edition of staging TNM of Union Internationale Contre
Le Cancer (UICC) in 2009. ** P < 0.01
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cancer cells. Our results highlighted the importance of
the upregulation of the miR-199a-5p in the prevention
of the metastatic ability of the bladder cancer cells. On
the other hand, we also observed that miR-199a-5p
could directly target the 3′UTR of CCR7 and regulate
the expression of MMP-9 and EMT-related proteins like
vimentin and E-cadherin, eventually suppress the pro-
gression of bladder cancer.
In this study, we firstly observed that miR-199a-5p
was downregulated in both human bladder cancer tis-
sues samples and bladder cancer cells compared with
that in paired adjacent normal tissues or normal epithe-
lial cell line SV-HUC-1 by qRT-PCR, which was consist-
ent with the previous studies [19, 20]. As for the
expression of CCR7, there was an inverse relationship
with that of miR-199a-5p. In addition, both CCR7
upregulation and miR-199a-5p downregulation were
significantly involved in bladder cancer clinicopathologi-
cal features.
Recent studies have established that miR-199a was sig-
nificantly abnormally expressed in several solid tumors
and functioned as oncogene or tumor suppressor. For
instance, miR-199a-3p modulated cell cycle, invasion
capability, and doxorubicin sensitivity by targeting mam-
malian target of rapamycin (mTOR) and c-Met in
human hepatocarcinoma cells [21]. Besides, miR-199a-
5p was involved in cell proliferation, migration and
apoptosis by targeting of multiple myeloma-related
angiogenesis [22]. Moreover, miR-199a-5p overexpres-
sion promoted cell migration and invasion by targeting
klotho in gastric cancer cells [23]. In present study, our
results found that overexpression of miR-199a-5p could
inhibit bladder cancer cell migration and invasion using
wound-healing assay and Matrigel invasion assay.
To explore whether CCR7 was a potential target of
miR-199a-5p, we employed luciferase reporter assay and
verified this hypothesis. After transfection with miR-
199a-5p in T24 cells, the relative luciferase activity was
obviously suppressed and CCR7 expression was de-
creased compared with the negative control. Recent
studies suggested that MMP-9 and EMT-related proteins
played a crucial role in the process of cell invasion and
metastasis that involves loss of cell–cell adhesion and in-
creased cell mobility, and CCR7 might have an effect on
metastasis of bladder cancer by regulating MMP-9 and
EMT-related proteins [24–28]. Our results showed that
Table 2 Correlation between CCR7 expression and clinicopathological characteristics of bladder cancer patients
Characteristics Total Expression of CCR7 P value
High (n = 30) Low (n = 10)
Age 0.368
≤ 60 22 18(81.8 %) 4(18.2 %)
> 60 18 12(66.7 %) 6(33.3 %)
Gender 0.234
Male 27 10(37 %) 17(63 %)
Female 13 3(23.1 %) 10(76.9 %)
TNM stage 0.011*
0/I 16 8(93.8 %) 1(6.2 %)
II/III/IV 24 15(62.5 %) 9(37.5 %)
Tumor size 0.675
< 3 cm 15 8(53.3 %) 7(46.7 %)
≥ 3 cm 25 22(88.8 %) 3(11.2 %)
Histological grade 0.001**
PUNLMP/Low-grade 18 10(55.6 %) 8(44.4 %)
High-grade 22 20(90.9 %) 2(9.1 %)
Tumor invasion depth (T) <0.001**
Tis, Ta, T1 17 10(58.8 %) 7(41.2 %)
T2, T3 or above 23 20(87 %) 3(13 %)
Lymph node metastasis (N) <0.001**
N0 12 8(66.7 %) 4(33.3 %)
N1 or above 28 22(78.6 %) 6(21.4 %)
PUNLMP papillary urothelial neoplasm of low malignant potential; Low-grade lowgrade papillary urothelial carcinoma; High-grade high-grade papillary urothelial
carcinoma (http://www.pathology.jhu.edu/bladdercancer/disease_info.cfm). TNM according to the seventh edition of staging TNM of Union Internationale Contre
Le Cancer (UICC) in 2009. ** P < 0.01
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Fig. 2 (See legend on next page.)
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overexpression of miR-199a-5p could significant de-
crease the expression of MMP-9 and vimentin, and obvi-
ously enhance the expression of E-cadherin. Taken
together, our findings elucidate a novel role of miR-
199a-5p in the suppression of cell metastasis through
regulation MMP-9 and EMT-related genes by targeting
CCR7 in bladder cancer.
Although miR-199a-5p in this study showed a good
control to cell metastasis by targeting CCR7 in human
bladder cancer, it should be noted that this study only
revealed the effect of miR-199a-5p on cell metastasis.
Future studies will make great efforts to explore more
functional role of miR-199a-5p in the tumorigenesis and
progression of human bladder cancer.
Conclusion
In summary, our present study revealed that downregu-
lation of miR-199a-5p was positively correlated with
clinicopathological factors in bladder cancer. Collect-
ively, these results add newer insights into the multifa-
ceted role played by miR-199a-5p/CCR7 in bladder
cancer, prompting for the first time this miRNA/chemo-
kine axis that regulates cell metastasis. These data sup-
ported miR-199a-5p as a potential therapeutic agent and
diagnostic marker of bladder cancer.
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